A CHECKLIST FOR SUITABILITY OF BIOMARKERS AS SURROGATE END-POINTS IN CHEMOPREVENTION OF BREAST-CANCER

被引：0
|
作者：
BOGOCH, S
BOGOCH, ES
机构：
[1] BOSTON UNIV, SCH MED, BOSTON, MA 02215 USA
[2] ONCOLAB, BOSTON, MA 02215 USA
来源：
JOURNAL OF CELLULAR BIOCHEMISTRY | 1994年
关键词：
ANTIMALIGNIN; CANCER ANTIBODY; CANCER ANTIGEN; CANCER VACCINE; CYTOTOXICITY; GLYCOPROTEINS; IMMUNOSURVEILLANCE; MALIGNIN;
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
By reference to a ''checklist'' of requirements for substances or processes to qualify as surrogate endpoint biomarkers, both malignin and antimalignin antibody are found to be suitable for use in breast cancer chemoprevention trials. Antimalignin has been shown to be highly specific and sensitive, modulatable and reversible, detectable early in appearance of malignancy and upon recovery therefrom, and differentially expressed in high-risk individuals as compared with the general population. (C) 1994 Wiley-Liss, Inc.
引用
收藏
页码：173 / 185
页数：13
相关论文
共 50 条
  • [21] INTRAEPITHELIAL NEOPLASIA, SURROGATE END-POINT BIOMARKERS, AND CANCER CHEMOPREVENTION
    BOONE, CW
    KELLOFF, GJ
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1993, : 37 - 48
  • [22] Biological surrogate end-points in cancer trials: Potential uses, benefits and pitfalls
    Cooper, R
    Kaanders, JHAM
    EUROPEAN JOURNAL OF CANCER, 2005, 41 (09) : 1261 - 1266
  • [23] RIGHT, WRONG, AND SURROGATE END-POINTS .1.
    GELMAN, S
    ANESTHESIOLOGY, 1995, 82 (04) : 1084 - 1084
  • [24] BREAST-CANCER CHEMOPREVENTION
    COSTA, A
    EUROPEAN JOURNAL OF CANCER, 1993, 29A (04) : 589 - 592
  • [25] CHEMOPREVENTION OF BREAST-CANCER
    ATIBA, JO
    MEYSKENS, FL
    SEMINARS IN ONCOLOGY, 1992, 19 (03) : 220 - 229
  • [26] Hemodynamic surrogate end-points in phase I studies?
    DeMay, C
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1997, 35 (04) : 175 - 179
  • [27] BREAST-CANCER CHEMOPREVENTION
    BRIERE, M
    SPYRATOS, F
    BULLETIN DU CANCER, 1994, 81 (08) : 703 - 705
  • [28] CHEMOPREVENTION OF BREAST-CANCER
    POWLES, TJ
    HARDY, JR
    ASHLEY, SE
    COSGROVE, D
    DAVEY, JB
    DOWSETT, M
    MCKINNA, A
    NASH, AG
    RUNDLE, SK
    SINNETT, HD
    TILLYER, CR
    TRELEAVEN, JG
    BREAST CANCER RESEARCH AND TREATMENT, 1989, 14 (01) : 23 - 31
  • [29] CHEMOPREVENTION OF BREAST-CANCER
    POWLES, TJ
    DAVEY, J
    MCKINNA, A
    ACTA ONCOLOGICA, 1989, 28 (06) : 865 - 867
  • [30] Outcomes and costs of Surrogate End-points (SES) and biomarkers in phase I oncology clinical trials
    Goulart, BHL
    Roberts, TG
    Liu, Y
    Clark, JW
    VALUE IN HEALTH, 2004, 7 (03) : 248 - 248
12345